|
Name |
alpha,beta-Dehydrocurvularin
|
| Molecular Formula | C16H18O5 | |
| IUPAC Name* |
(9E)-13,15-dihydroxy-5-methyl-4-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraene-3,11-dione
|
|
| SMILES |
CC1CCC/C=C/C(=O)C2=C(CC(=O)O1)C=C(C=C2O)O
|
|
| InChI |
InChI=1S/C16H18O5/c1-10-5-3-2-4-6-13(18)16-11(8-15(20)21-10)7-12(17)9-14(16)19/h4,6-7,9-10,17,19H,2-3,5,8H2,1H3/b6-4+
|
|
| InChIKey |
AVIRMQMUBGNCKS-GQCTYLIASA-N
|
|
| Synonyms |
alpha,beta-Dehydrocurvularin; (9E)-13,15-dihydroxy-5-methyl-4-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraene-3,11-dione; 10, 11-Dehydrocurvularin; MLS000876814; CHEMBL482050; MEGxm0_000082; ACon0_000612; ACon1_000724; 4,5,6,7-Tetrahydro-11,13-dihydroxy-4-methyl-2H-3- benzoxacyclododecin-2,10-(1H)-dione; 4,5,6,7-Tetrahydro-11,13-dihydroxy-4-methyl-2H-3-benzoxacyclododecin-2,10-(1H)-dione; CHEBI:181240; 1095588-70-7; NCGC00380665-01; BD162702; SMR000440573; BRD-A61186587-001-01-9; (8E)-11,13-dihydroxy-4-methyl-2,4,5,6,7,10-hexahydro-1H-3-benzoxacyclododecine-2,10-dione; NCGC00380665-01_C16H18O5_(8E)-11,13-Dihydroxy-4-methyl-4,5,6,7-tetrahydro-2H-3-benzoxacyclododecine-2,10(1H)-dione
|
|
| CAS | NA | |
| PubChem CID | 14314897 | |
| ChEMBL ID | CHEMBL482050 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 290.31 | ALogp: | 3.0 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 83.8 | Aromatic Rings: | 2 |
| Heavy Atoms: | 21 | QED Weighted: | 0.716 |
| Caco-2 Permeability: | -4.642 | MDCK Permeability: | 0.00001800 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.034 |
| 30% Bioavailability (F30%): | 0.537 |
| Blood-Brain-Barrier Penetration (BBB): | 0.245 | Plasma Protein Binding (PPB): | 86.97% |
| Volume Distribution (VD): | 0.924 | Fu: | 9.56% |
| CYP1A2-inhibitor: | 0.792 | CYP1A2-substrate: | 0.097 |
| CYP2C19-inhibitor: | 0.35 | CYP2C19-substrate: | 0.062 |
| CYP2C9-inhibitor: | 0.391 | CYP2C9-substrate: | 0.939 |
| CYP2D6-inhibitor: | 0.821 | CYP2D6-substrate: | 0.3 |
| CYP3A4-inhibitor: | 0.652 | CYP3A4-substrate: | 0.174 |
| Clearance (CL): | 16.444 | Half-life (T1/2): | 0.899 |
| hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.097 |
| Drug-inuced Liver Injury (DILI): | 0.825 | AMES Toxicity: | 0.139 |
| Rat Oral Acute Toxicity: | 0.053 | Maximum Recommended Daily Dose: | 0.457 |
| Skin Sensitization: | 0.717 | Carcinogencity: | 0.845 |
| Eye Corrosion: | 0.022 | Eye Irritation: | 0.19 |
| Respiratory Toxicity: | 0.398 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005419 | ![]() |
1.000 | D07MGA | ![]() |
0.322 | ||
| ENC005643 | ![]() |
1.000 | D04AIT | ![]() |
0.247 | ||
| ENC005417 | ![]() |
1.000 | D0K8KX | ![]() |
0.242 | ||
| ENC005418 | ![]() |
0.735 | D00ZFP | ![]() |
0.237 | ||
| ENC005138 | ![]() |
0.710 | D0H6QU | ![]() |
0.237 | ||
| ENC003140 | ![]() |
0.706 | D0K7LU | ![]() |
0.230 | ||
| ENC001430 | ![]() |
0.657 | D04JHN | ![]() |
0.229 | ||
| ENC005644 | ![]() |
0.639 | D0J4IX | ![]() |
0.224 | ||
| ENC003117 | ![]() |
0.630 | D02NSF | ![]() |
0.224 | ||
| ENC005137 | ![]() |
0.613 | D07GRH | ![]() |
0.220 | ||